CO2017012454A2 - Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia - Google Patents
Secuencias de uricasa adecuadas para el tratamiento de hiperuricemiaInfo
- Publication number
- CO2017012454A2 CO2017012454A2 CONC2017/0012454A CO2017012454A CO2017012454A2 CO 2017012454 A2 CO2017012454 A2 CO 2017012454A2 CO 2017012454 A CO2017012454 A CO 2017012454A CO 2017012454 A2 CO2017012454 A2 CO 2017012454A2
- Authority
- CO
- Colombia
- Prior art keywords
- hyperuricemia
- treatment
- sequences suitable
- uricase
- uricase sequences
- Prior art date
Links
- 201000001431 Hyperuricemia Diseases 0.000 title abstract 2
- 108010092464 Urate Oxidase Proteins 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562162280P | 2015-05-15 | 2015-05-15 | |
| PCT/US2016/032415 WO2016187026A1 (en) | 2015-05-15 | 2016-05-13 | Improved uricase sequences and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017012454A2 true CO2017012454A2 (es) | 2018-04-30 |
Family
ID=57320301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0012454A CO2017012454A2 (es) | 2015-05-15 | 2017-12-01 | Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11098289B2 (enExample) |
| EP (1) | EP3294322A4 (enExample) |
| JP (2) | JP2018515101A (enExample) |
| KR (1) | KR20180002828A (enExample) |
| CN (1) | CN107614007B (enExample) |
| AU (2) | AU2016265677B2 (enExample) |
| BR (1) | BR112017024212A2 (enExample) |
| CA (1) | CA2984926A1 (enExample) |
| CL (1) | CL2017002774A1 (enExample) |
| CO (1) | CO2017012454A2 (enExample) |
| HK (1) | HK1252542A1 (enExample) |
| IL (1) | IL255403A0 (enExample) |
| MX (1) | MX2017014547A (enExample) |
| MY (1) | MY190411A (enExample) |
| RU (1) | RU2752497C2 (enExample) |
| SG (2) | SG10201910522TA (enExample) |
| WO (1) | WO2016187026A1 (enExample) |
| ZA (1) | ZA201708507B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201910522TA (en) | 2015-05-15 | 2020-01-30 | Medimmune Llc | Improved uricase sequences and methods of treatment |
| CN106554948B (zh) * | 2015-09-29 | 2019-06-25 | 上海生物制品研究所有限责任公司 | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 |
| CN112410313A (zh) * | 2019-08-20 | 2021-02-26 | 中国科学院上海药物研究所 | 一种高热稳定性尿酸酶及其应用 |
| CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
| WO2021083278A1 (en) * | 2019-10-29 | 2021-05-06 | Westlake Therapeutics (Hangzhou) Co. Limited | Engineering red blood cells for treating gout and hyperuricemia diseases |
| KR20230059777A (ko) | 2020-09-25 | 2023-05-03 | 주식회사 프로앱텍 | 요산산화효소-알부민 접합체, 그 제조방법 및 용도 |
| WO2022081774A1 (en) * | 2020-10-13 | 2022-04-21 | University Of Florida Research Foundation, Incorporated | Self-assembling uricase fusion peptides |
| JP2023548496A (ja) | 2020-11-03 | 2023-11-17 | プロタリクス リミテッド | 修飾ウリカーゼ及びその使用 |
| CN114438048B (zh) * | 2020-11-05 | 2024-10-22 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
| CN115197923B (zh) * | 2021-04-09 | 2024-11-26 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
| KR20240049312A (ko) * | 2021-07-08 | 2024-04-16 | 주식회사 프로앱텍 | Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도 |
| KR20240083169A (ko) * | 2021-09-23 | 2024-06-11 | 주식회사 프로앱텍 | Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트 |
| US20250241999A1 (en) * | 2021-10-15 | 2025-07-31 | Georgia State University Research Foundation, Inc. | Delivery of therapeutic recombinant uricase using nanoparticles |
| CN119752761B (zh) * | 2025-03-07 | 2025-06-17 | 北京化工大学 | 一种高产heparosan的基因工程菌及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09154581A (ja) * | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | ウリカーゼを生産する実質上純粋な微生物 |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| ATE498409T1 (de) * | 1998-08-06 | 2011-03-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| RU2290439C2 (ru) | 1998-08-06 | 2006-12-27 | Дьюк Юниверсити | Рекомбинантный белок уриказы млекопитающего для конъюгирования с пэг, молекула нуклеиновой кислоты, кодирующая его, вектор для его экспрессии, способ его получения и применение |
| HU228916B1 (en) * | 1998-08-06 | 2013-06-28 | Mountain View Pharmaceuticals | Polyethylen-glycol/carbamate oxydase conjugates and pharmaceutical compositions containing thereof |
| NZ513077A (en) * | 1999-01-14 | 2004-03-26 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| SG10201706384VA (en) * | 2005-04-11 | 2017-09-28 | Crealta Pharmaceuticals Llc | A variant form of urate oxidase and use thereof |
| NZ562292A (en) * | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US20130305398A1 (en) * | 2012-02-16 | 2013-11-14 | Marie Coffin | Genes and uses for plant enhacement |
| DK2840142T3 (en) * | 2007-06-06 | 2019-03-18 | Monsanto Technology Llc | Genes and uses for plant improvement |
| KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
| CN103184208B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用 |
| SG10201910522TA (en) | 2015-05-15 | 2020-01-30 | Medimmune Llc | Improved uricase sequences and methods of treatment |
-
2016
- 2016-05-13 SG SG10201910522TA patent/SG10201910522TA/en unknown
- 2016-05-13 SG SG11201708759YA patent/SG11201708759YA/en unknown
- 2016-05-13 CA CA2984926A patent/CA2984926A1/en active Pending
- 2016-05-13 AU AU2016265677A patent/AU2016265677B2/en not_active Ceased
- 2016-05-13 BR BR112017024212A patent/BR112017024212A2/pt not_active IP Right Cessation
- 2016-05-13 RU RU2017143580A patent/RU2752497C2/ru active
- 2016-05-13 WO PCT/US2016/032415 patent/WO2016187026A1/en not_active Ceased
- 2016-05-13 JP JP2017559314A patent/JP2018515101A/ja active Pending
- 2016-05-13 EP EP16797021.9A patent/EP3294322A4/en not_active Withdrawn
- 2016-05-13 HK HK18111855.1A patent/HK1252542A1/zh unknown
- 2016-05-13 KR KR1020177035108A patent/KR20180002828A/ko not_active Ceased
- 2016-05-13 MX MX2017014547A patent/MX2017014547A/es unknown
- 2016-05-13 CN CN201680027432.9A patent/CN107614007B/zh not_active Expired - Fee Related
- 2016-05-13 US US15/573,993 patent/US11098289B2/en active Active
- 2016-05-13 MY MYPI2017704267A patent/MY190411A/en unknown
-
2017
- 2017-11-02 IL IL255403A patent/IL255403A0/en unknown
- 2017-11-03 CL CL2017002774A patent/CL2017002774A1/es unknown
- 2017-12-01 CO CONC2017/0012454A patent/CO2017012454A2/es unknown
- 2017-12-14 ZA ZA2017/08507A patent/ZA201708507B/en unknown
-
2018
- 2018-10-23 US US16/167,765 patent/US10883087B2/en active Active
-
2020
- 2020-11-18 US US16/951,764 patent/US20210254024A1/en not_active Abandoned
-
2021
- 2021-08-06 JP JP2021130287A patent/JP2021184733A/ja active Pending
-
2022
- 2022-01-10 AU AU2022200104A patent/AU2022200104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201910522TA (en) | 2020-01-30 |
| RU2752497C2 (ru) | 2021-07-28 |
| EP3294322A4 (en) | 2018-12-12 |
| US11098289B2 (en) | 2021-08-24 |
| RU2017143580A3 (enExample) | 2019-12-16 |
| CA2984926A1 (en) | 2016-11-24 |
| CN107614007B (zh) | 2022-03-25 |
| BR112017024212A2 (pt) | 2018-07-17 |
| CL2017002774A1 (es) | 2018-04-06 |
| AU2022200104A1 (en) | 2022-02-03 |
| WO2016187026A1 (en) | 2016-11-24 |
| IL255403A0 (en) | 2017-12-31 |
| MY190411A (en) | 2022-04-21 |
| US20210254024A1 (en) | 2021-08-19 |
| CN107614007A (zh) | 2018-01-19 |
| AU2016265677A1 (en) | 2018-01-04 |
| AU2016265677B2 (en) | 2021-12-09 |
| RU2017143580A (ru) | 2019-06-17 |
| EP3294322A1 (en) | 2018-03-21 |
| KR20180002828A (ko) | 2018-01-08 |
| JP2018515101A (ja) | 2018-06-14 |
| JP2021184733A (ja) | 2021-12-09 |
| US20180258406A1 (en) | 2018-09-13 |
| HK1252542A1 (zh) | 2019-05-31 |
| US10883087B2 (en) | 2021-01-05 |
| US20190048327A1 (en) | 2019-02-14 |
| MX2017014547A (es) | 2018-03-15 |
| SG11201708759YA (en) | 2017-11-29 |
| ZA201708507B (en) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017012454A2 (es) | Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia | |
| EP4477662A3 (en) | Nucleic acid molecules and uses thereof | |
| CY1124742T1 (el) | 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv | |
| CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
| ZA202004764B (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| WO2018115507A3 (en) | Henipavirus vaccine | |
| CL2019000732A1 (es) | Tratamiento avv de la enfermedad de huntington. | |
| CR20170359A (es) | Oligómetros antisentido de tau y usos de estos | |
| MD4733B1 (ro) | Anticorpi anti-TIGIT | |
| EA201291195A1 (ru) | Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1 | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
| EA201491780A1 (ru) | Мутанты c-raf, придающие резистентность к ингибиторам raf | |
| MX2018001298A (es) | Agente inductor de inmunidad. | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| MX2017013480A (es) | Composicion farmaceutica para tratar y/o prevenir el cancer. | |
| BR112018073300A2 (pt) | métodos para tratamento de doenças associadas com as células ilc3 | |
| RU2014142752A (ru) | Способы воздействия на экспрессию гена лактазы | |
| EA201691835A1 (ru) | Аллостерические модуляторы капсидного белка гепатита в |